The specter of generic challenges has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the future of related pharmaceutical stakes. While initial years saw substantial profits, the intellectual property end has allowed the way for cheaper copies, likely diminishing revenue and posing a genuine danger for